New FDA Approved Indications for Topical Treatment of Tick Infestation in Cats

Fluralaner topical solution (Bravecto) and fluralaner and moxidectin topical solution (Bravecto Plus) are now indicated for the treatment and control of Asian long-horned tick infestations in cats.

Merck Animal Health announced the new label indication of fluralaner topical solution (Bravecto) and fluralaner topical solution and moxidectin (Bravecto Plus) for the treatment and control of Asian long-horned tick infestations in the cats. Both products are the first U.S. products labeled for both the treatment and control of Asian long-horned tick infestations.

The Asian long-horned tick is an invasive ixodid tick native to Japan, China, eastern Russia, and Korea. As of December 2021, the species was localized to more than a third of the United States, according to Merck. These ticks have the potential to quickly become an important tick species within pet populations and are known to carry various viral, bacterial and protozoan agents.

“We are committed to protecting pets and their owners from parasites that pose risks to animal and human health. With the new indication [for these products], we can expand our ability to care for companion animals by offering an even broader range of parasite protection for cats,” Dominique Sims, DVM, Associate Director, Scientific Affairs, Merck Animal Health, said in a statement. organizational. “Veterinarians can now recommend a treatment option that offers more versatile protection than traditional flea and tick offerings, while giving cat owners peace of mind knowing their pet is safe from the infestations.”

Merck’s fluralaner topical solution for cats was previously indicated for the treatment and prevention of flea infestations, the treatment and control of blacklegged ticks and Asian long-horned ticks for 12 weeks, and the treatment and control of control of American dog tick infestations for 8 weeks.

Additionally, fluralaner and moxidectin topical solution is also indicated for heartworm prevention, treatment of intestinal roundworm and hookworm infections, ability to kill adult fleas, treatment and prevention of fleas for 2 months, and the treatment and control of black-legged ticks, American dog ticks and Asian long-horned ticks for 2 months.

Reference

US FDA approves new indication for Bravecto (fluralaner topical solution) for cats and Bravecto Plus (fluralaner topical solution and moxidectin) for cats from Merck Animal Health. Press release. September 6, 2022. Accessed September 8, 2022. https://www.merck-animal-health-usa.com/newsroom/fda-approves-new-indication-for-bravecto

About Michael Bill

Check Also

Putin doesn’t think invading Ukraine a ‘mistake’: Scholz | Russo-Ukrainian War

German Chancellor says there is no indication Putin has changed his stance on Ukraine as …